Cost and cost-effectiveness of adjuvant trastuzumab in the real world setting: A study of the Southeast Netherlands Breast Cancer Consortium

BACKGROUND: We assessed the real world costs and cost-effectiveness of the addition of trastuzumab in HER2 positive early breast cancer compared to chemotherapy alone in the Dutch daily practice as opposed to the results based on trial data and based on a subset of patients that were treated accordi...

Descripción completa

Detalles Bibliográficos
Autores principales: Seferina, Shanly C., Ramaekers, Bram L.T., de Boer, Maaike, Dercksen, M. Wouter, van den Berkmortel, Franchette, van Kampen, Roel J.W., van de Wouw, Agnès J., Voogd, Adri C., Tjan Heijnen, Vivianne C.G., Joore, Manuela A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Clinical Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5668034/
https://www.ncbi.nlm.nih.gov/pubmed/29108301
http://dx.doi.org/10.18632/oncotarget.16985

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5668034/
https://www.ncbi.nlm.nih.gov/pubmed/29108301
http://dx.doi.org/10.18632/oncotarget.16985

Ejemplares similares